Affordable Access

deepdyve-link
Publisher Website

Evaluating the role of nab-paclitaxel (Abraxane) in women with aggressive metastatic breast cancer.

Authors
  • Ciruelos, Eva
  • Jackisch, Christian
Type
Published Article
Journal
Expert Review of Anticancer Therapy
Publisher
Informa UK (Taylor & Francis)
Publication Date
May 01, 2014
Volume
14
Issue
5
Pages
511–521
Identifiers
DOI: 10.1586/14737140.2014.883922
PMID: 24575935
Source
Medline
License
Unknown

Abstract

Nab-paclitaxel (Abraxane(®)) is an albumin-bound form of paclitaxel that utilizes the natural properties of albumin to improve paclitaxel delivery to the tumor. It is licensed for use in metastatic breast cancer (MBC) at a dose of 260 mg/m(2) Q3W based on its superior therapeutic index versus conventional paclitaxel 175 mg/m(2) Q3W demonstrated in a Phase III study. In a post-hoc analysis, nab-paclitaxel treatment was associated with rapid and dramatic tumor responses in patients with poor prognostic factors (visceral dominant disease, ≥3 metastatic lesions), suggesting it may be a preferred treatment for these patients. Moreover, significant efficacy has been seen with nab-paclitaxel 100 and 150 mg/m(2) QW 3/4, suggesting it may be possible to tailor use of this agent in the future.

Report this publication

Statistics

Seen <100 times